All In Biotech

Drug Trial Radar · NCT07722611

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Jun 25, 2032

Study completion Nov 30, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, also called MK-3543, can treat PV. In this study, researchers will compare bomedemstat to 2 usual treatments for PV. The goal of this study is to learn if more participants who take bomedemstat reach healthy blood cell counts and avoid major health problems from PV, compared to those who receive a usual treatment.

Conditions

  • Polycythemia Vera

Interventions

  • BomedemstatDrug

    Oral Capsule

  • RuxolitinibDrug

    Oral Tablet

  • Ropeginterferon alfa-2bDrug

    Subcutaneous Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinicohematologic Response (CHR) RateTime frame: Up to approximately Week 52

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Medical Oncology Hematology Consultants (MOHC) ( Site 8002)

    Newark, Delaware · Recruiting

  • Maryland Oncology Hematology (MOH) ( Site 8001)

    Columbia, Maryland · Recruiting

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8004)

    Eugene, Oregon · Recruiting

  • University of Virginia ( Site 5031)

    Charlottesville, Virginia · Recruiting

  • Princess Margaret Cancer Centre ( Site 4002)

    Toronto, Ontario, Canada · Recruiting

  • Soroka Medical Center ( Site 2607)

    Beersheba, Israel · Recruiting

  • Hadassah Medical Center ( Site 2604)

    Jerusalem, Israel · Recruiting

  • Sourasky Medical Center ( Site 2602)

    Tel Aviv, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.